MarketVIEW Travel Vaccines  ·  2020 Edition

West Nile Virus (WNV)
Vaccines Forecast

West Nile virus is a mosquito-borne arbovirus with an established, growing footprint in North America and an expanding transmission range across Europe, yet more than a quarter-century after it first arrived in the United States, no human vaccine has ever reached the market. This report sets out the current disease background, a pipeline littered with stalled clinical candidates, and the commercial forecast question every developer must still answer: who exactly is the target population for routine WNV vaccination, and who pays for it. VacZine Analytics has tracked vector-borne and travel disease markets since our earliest editions, and this comprehensive, wide-geography assessment reflects that long-standing expertise.

WNV: Leading US Mosquito-Borne Disease Now Endemic Across Southern/Eastern Europe Zero Licensed Human Vaccines Wide Geography Forecast to 2035
Product catalogue
VAMV039
2020 edition

Format
Executive presentation + Excel model
Coverage
Major Western markets
Scenarios
LO / BASE / HI uptake, by age group
Forecast horizon
To 2035
Approach
Value ($m)/volume (mio doses), launch timing & pricing
Base edition
2020
Availability
Syndicated / bespoke
#1
Leading cause of mosquito-borne
disease in the continental US
1 in 150
Infections progressing to
neuroinvasive disease
14+
European countries reporting
locally-acquired cases, 2025 season
0
Licensed human WNV vaccines,
despite decades of trials
Disease background

A mosquito-borne arbovirus with a widening footprint, and still no human vaccine

West Nile virus sits squarely within VacZine Analytics' long-standing travel and vector-borne disease coverage. This review sets out the virology, transmission cycle and clinical spectrum of WNV, before turning to its current epidemiology in the US and its expanding range across Europe.

CDC ArboNET & ECDC surveillance data, 2025/26 season

Pathogen overview - West Nile virus (WNV)

West Nile virus is a single-stranded RNA flavivirus, related to Japanese encephalitis, St Louis encephalitis and Zika virus, maintained in nature through an enzootic transmission cycle between Culex mosquitoes and wild bird reservoir hosts. Birds act as amplifying hosts, sustaining virus circulation and geographic spread as infected mosquitoes feed across bird populations; humans and horses are incidental, dead-end hosts who become infected only when bitten by an already-infected mosquito, and cannot themselves transmit the virus onward through further mosquito bites. This ecology, dependent on local mosquito and bird populations, climate and rainfall patterns, is what gives WNV disease activity its characteristically episodic, geographically patchy, season-by-season variability, a factor that has repeatedly complicated vaccine clinical trial design.

The clinical spectrum of WNV infection is wide. Around 8 in 10 infections are asymptomatic. Most symptomatic cases present as West Nile fever, a self-limiting febrile illness with headache, fatigue, body aches and sometimes a rash. In a minority, currently estimated at roughly 1 in 150 infections, the virus crosses into the central nervous system to cause neuroinvasive disease, encephalitis, meningitis or an acute flaccid paralysis resembling poliomyelitis, which can be fatal or leave lasting neurological impairment. Risk of severe, neuroinvasive disease rises sharply with age and with immunosuppression: adults 65 and older face a risk of neuroinvasive disease several-fold higher than younger adults, and roughly 1 in 10 people who develop neuroinvasive disease die from it. There is no specific antiviral treatment; care remains supportive.

In the United States, where WNV first appeared in New York in 1999, it has since become firmly established nationwide and now stands as the leading cause of domestically-acquired mosquito-borne disease in the continental US in most years. Having caused an estimated 29,606 clinical cases and 1,423 deaths between 1999 and 2009, CDC ArboNET's cumulative national totals have continued climbing steadily through subsequent seasons; the 2025 season alone added a further 1,862 reported human cases and 134 deaths across 42 states, with Colorado, Illinois and Texas among the hardest hit, underscoring that this is an established, recurring, and far from historical burden. Because most infections are never diagnosed, true case numbers are understood to run many times higher than these reported counts.

Europe's experience has moved in a similar direction. WNV transmission is now considered established and expanding across southern, central and eastern Europe, with the 2025 transmission season, running from May to October, seeing at least 14 countries, including Italy, Greece, Serbia, France, Romania, Spain and Bulgaria, report locally-acquired human cases, and roughly 95 associated deaths by early November. Italy alone accounted for the large majority of the continent's cases. Milder winters, shifting mosquito and bird ecology, and intensified surveillance have all been cited as contributing to this steady territorial expansion, which increasingly mirrors the pattern already seen across the US since 1999, and reinforces the case for a genuinely wide-geography commercial assessment rather than a US-only view.

2026 Leading US mosquito-borne disease most seasons  |  1,862 US cases / 134 deaths in 2025  |  14+ European countries with local transmission in 2025  |  No licensed human vaccine after 25+ years
Product & competitor landscape

A quarter-century of clinical attempts, and still no approved candidate

Human WNV vaccine development has an unusually long, unusually unsuccessful history for a pathogen this well characterised. Several candidates have cleared early-phase human trials on immunogenicity and safety; none has advanced to Phase III or licensure. This report treats that pattern candidly, as a market-intelligence finding in its own right rather than a footnote.

  • Sanofi PasteurStalled after Phase II
    ChimeriVax-WN02 Live chimeric, yellow-fever 17D backbone
    A live chimeric vaccine substituting WNV envelope genes into the well-established yellow fever 17D vaccine backbone. It proved well tolerated and strongly immunogenic in both younger and elderly adults across a Phase I and two Phase II trials, yet the programme did not progress to Phase III or licensure, and has not been reported active for well over a decade.
  • NIAID / Emory / IDCRCPhase I complete
    HydroVax-001 Hydrogen-peroxide-inactivated, whole-virus
    An inactivated whole-virus candidate using a novel hydrogen-peroxide inactivation method designed to preserve native viral structure. A placebo-controlled Phase I dose-escalation trial in healthy adults found it safe and well tolerated with no serious adverse events; academic and public-sector development has continued in a research capacity, but no industry partner has advanced it toward licensure.
  • Multiple historical developersAll discontinued or dormant
    DNA, recombinant subunit & other candidates
    Beyond ChimeriVax-WN02 and HydroVax-001, at least half a dozen further WNV candidates, spanning DNA-plasmid, recombinant subunit and other live-attenuated platforms, have completed Phase I or Phase II human testing since the early 2000s. None has advanced past Phase II; several programmes appear to have lapsed entirely as sponsors redirected resources elsewhere.
  • mRNA-platform developersNo dedicated WNV programme identified
    Post-COVID mRNA flavivirus interest has not yet extended to WNV
    The post-COVID surge in mRNA flavivirus vaccine investment has concentrated on Zika, dengue and other higher-visibility targets. As of this edition, no major mRNA developer, including Moderna, has a disclosed, dedicated clinical-stage WNV programme, a gap this report views as a further sign of unresolved commercial appetite rather than a scientific barrier.
  • Multiple manufacturersLicensed for horses
    Veterinary WNV vaccines
    Several inactivated and recombinant WNV vaccines are licensed and routinely used in horses across the US and Europe, demonstrating that effective WNV vaccine antigens exist and work; the barrier to a human product has never primarily been the underlying science.
The honest finding
0 licensed

No WNV vaccine candidate has ever reached human licensure, despite more than two decades of clinical development and several scientifically successful early-phase trials. A 2024 multi-stakeholder meeting on human WNV vaccine development, summarised in the literature during 2025, was explicit about why: episodic, geographically patchy transmission makes Phase III efficacy trials extremely difficult to power and site; there is still no validated surrogate endpoint to predict clinical protection; standardised reagents and assays remain underdeveloped; and, most fundamentally, minimal commercial and economic support exists because no developer has yet identified a clear, payer-recognised target population for routine WNV vaccination. Unlike the horse market, where a defined, insurable animal population justifies a veterinary product, the human addressable population is diffuse, seasonal and geographically shifting. This is precisely the commercial question the VacZine Analytics model exists to quantify, scenario by scenario, market by market.

Scope of analysis

A wide-geography commercial model, built for a genuinely difficult market

This is a comprehensive, wide geographic focus report, well received by clients in the field for the breadth of its country and scenario coverage. It has always sat within VacZine Analytics' Travel diseases portfolio, alongside our Japanese encephalitis, dengue, TBE and other vector-borne assessments.

Major Western-market demand forecast

Value ($m) and volume (mio doses) demand modelling to 2035 across major Western markets.

Competitor & pipeline review

Full review of ChimeriVax-WN02, HydroVax-001 and the broader history of stalled human candidates.

LO / BASE / HI scenario modelling

Launch timeframe, pricing and penetration estimates for LO, BASE and HI uptake scenarios per target age group.

Value & volume forecasts to 2035

Forecast horizon extended from the original 2030 model to 2035 for this refresh brief.

Disease burden & expanding range

Updated US and European epidemiology, including ECDC's expanding southern/central/eastern European footprint.

Target-population feasibility view

An honest assessment of the target-population question that has historically stalled WNV vaccine commercialisation.

Sample analysis

A glimpse of the commercial model

The table below shows a partial view of the market, geography and scenario framework. Full volume/value outputs, pricing assumptions and country-level data are in the licensed model.

MarketTarget age groupScenarioLaunch timeframeRevenue outcome
United StatesAdults 65+BASEIllustrativeModelled
Southern & Central EuropeAll ages, at-risk regionsLOIllustrativeModelled
CanadaAdults 65+HIIllustrativeModelled
█████████████████████████$██m (base)
█████████████████████████$██m (upside)
Total addressable - baseAll age groupsAll scenariosAll markets$███m
Full model in the licensed workbook
Major Western markets · to 2035 · LO/BASE/HI by target age group
Register interest →
Deliverables

What you receive

A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for organisations weighing the long-standing, unresolved WNV vaccine opportunity.

  • Executive presentation - virology, transmission cycle, clinical spectrum, global burden and full competitive/pipeline environment review
  • MS-Excel commercial demand model - value ($m) and volume (mio doses) predictions to 2035 across major Western markets
  • Scenario modelling - launch timeframe, pricing and penetration estimates for LO/BASE/HI uptake scenarios per target age group
  • Wide-geography coverage - major Western markets modelled individually and in aggregate
  • Competitor intelligence - ChimeriVax-WN02, HydroVax-001, historical candidates and the current mRNA-platform gap
  • Updated epidemiology module - current CDC ArboNET US case/death data and ECDC's expanding European surveillance data
  • Target-population feasibility assessment - the commercial question every WNV vaccine developer must still answer
Target audience

Built for organisations weighing a genuinely difficult commercial question

Most valuable to teams assessing whether, and how, a WNV vaccine could finally be commercialised, against a quarter-century of prior clinical attempts that stalled on the same underlying market question.

Vaccine developers

Positioning and commercial feasibility assessment for a WNV candidate against a long, difficult history of stalled precedents.

Corporate strategy & BD

Validate market structure and target-population scenarios before committing R&D or licensing capital to this market.

Investors & analysts

Independent assessment of why WNV vaccine programmes have historically stalled, and what would need to change.

Public health & travel medicine

Demand modelling to support risk communication and outbreak-response planning across expanding US and European ranges.

Researchers & academia

Comprehensive epidemiology, pipeline and market-access landscape for grant and vector-borne disease research planning.

Market access & policy

Pricing benchmarks and access-pathway assumptions for a market with no established reimbursement precedent.

About this analysis · VAMV039

VacZine Analytics has drawn on its long-standing expertise in Travel diseases since our earliest editions, tracking mosquito-borne and other vector-borne vaccine markets, including West Nile virus, Japanese encephalitis, dengue and tick-borne encephalitis, across major Western geographies. This is a very comprehensive report with wide geographic focus, well received by clients in the field for the depth of its scenario modelling and its candid treatment of a genuinely difficult commercial question. Few independent groups have followed the WNV vaccine field's repeated stalls as closely, and that recognised expertise underpins everything in the analysis.

This report was last published as the 2020 edition; any refresh would incorporate current CDC ArboNET US case and death data, ECDC's expanding European surveillance data, and a full review of the pipeline's continued lack of a licensed candidate, including the current absence of a dedicated mRNA-platform programme. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.

MarketVIEW · VAMV039 · Syndicated & bespoke

Syndicate the refresh - or commission the answer you need

Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc WNV vaccine analysis, a briefing call is included on request.